Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 6/20 | 0.38 |
| ▸ | CA9 | Q16790 | 6/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5232128 | 1.00 | L3MBTL1 (0.44) | L3MBTL1ATMMEN1KMT2AALDH1A1 | |
| SCHEMBL5232012 | 0.90 | ATM (0.39) | L3MBTL1ATMMEN1KMT2AALDH1A1 | |
| SCHEMBL5232008 | 0.90 | ATM (0.39) | L3MBTL1ATMMEN1KMT2AALDH1A1 | |
| SCHEMBL5230886 | 0.90 | LMNA (0.47) | L3MBTL1ATMKMT2AALDH1A1LMNA | |
| SCHEMBL5234937 | 0.90 | LMNA (0.47) | L3MBTL1ATMKMT2AALDH1A1LMNA | |
| SCHEMBL5233118 | 0.89 | CA12 (0.33) | L3MBTL1ATMMEN1KMT2AALDH1A1 | |
| SCHEMBL5233587 | 0.89 | ALDH1A1 (0.36) | MEN1KMT2AALDH1A1CA12CA9 | |
| SCHEMBL5233096 | 0.89 | CA12 (0.33) | L3MBTL1ATMMEN1KMT2AALDH1A1 | |
| SCHEMBL5233595 | 0.89 | ALDH1A1 (0.36) | MEN1KMT2AALDH1A1CA12CA9 | |
| SCHEMBL5230218 | 0.89 | ALDH1A1 (0.39) | L3MBTL1ATMMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730116-B1 | 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORP (US) | 2007-09-05 | — | — | EP | claimed |
| US-20070167507-A1 | 4-Carbox pyrazole derivatives useful as anti-viral agents | GLAXO GROUP LIMITED (GB) | 2007-07-19 | — | — | US | claimed |
| EP-1730116-B1 | 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORP (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20070167507-A1 | 4-Carbox pyrazole derivatives useful as anti-viral agents | GLAXO GROUP LIMITED (GB) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167507-A1 | 4-Carbox pyrazole derivatives useful as anti-viral agents | HAVCR2, RPL35, ZC3HAV1L | L3MBTL1 2059/4885ATM 4653/4885MEN1 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.